ArticleJournal of immunology (Baltimore, Md. : 1950)2025
Bcl-xL is important for the antiapoptotic activity of Gfi1 and is upregulated by Gfi1 through hemgn.
Article in Journal of immunology (Baltimore, Md. : 1950), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Gfi1 is a transcriptional repressor that plays a critical role in hematopoiesis. Gfi1 represses its target genes primarily through interacting with the histone demethylase LSD1 via its SNAG domain. A major function of Gfi1 is to inhibit DNA damage-induced apoptosis through its involvement in post-translational modifications and subsequent inhibition of p53 protein, and in PRMT1-dependent methylation of MRE11 and 53BP1, which is necessary for these proteins to function in DNA repair. We show here that Gfi1 inhibited apoptosis induced not only by DNA damage but also by growth factor withdrawal, inhibitory cytokine TGF-β and MYC activation. We further demonstrate that Gfi1 upregulated the expression of the pro-survival Bcl-2 family member Bcl-xL in a manner that was independent of p53. Bcl-xL overexpression partially rescued the hypersensitivity to DNA damage of Gfi1-knocked down leukemic cells and Gfi1-deficient mouse primary bone marrow (BM) cells. In contrast, Bcl-xL knockdown partially abolished the protective effect of Gfi1 on DNA damage-induced apoptosis. Notably, interaction with LSD1 was required and sufficient for Gfi1-mediaed upregulation of Bcl-xL, suggesting that Gfi1 may augment Bcl-xL expression by an indirect mechanism. We further demonstrate that Bcl-xL upregulation by Gfi1 was dependent on Hemgn upregulation, which results from Gfi1-mediated repression of PU.1. Our data reveal a novel mechanism by which Gfi1 inhibits apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.